Glucose intolerance in acromegaly;Zaburzenia gospodarki wȩglowodanowej w akromegalii

Przeglad Kardiodiabetologinczny

Volumn 4, Issue 2, 2009, Pages 90-93

  Maliszewska, Katarzyna ^a   Krȩtowski, Adam ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acromegaly; Diabetes mellitus

Indexed keywords

SOMATOMEDIN C;

ACROMEGALY; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; RISK FACTOR;

EID: 77953369307     PISSN: 18969666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complication of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-52.
2. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34: 1429-33.
3. Katz JR, Edwards R, Khan M, Conway GS. Acromegaly presenting with diabetic ketoacidosis. Postgrad Med J 1996; 72: 682-3.
4. Stelmachowska-Banaś M, Zdunowski P. Zgliczyński W. Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol 2009; 60: 20-4.
5. Szybiński Z. Polskie wieloośrodkowe badanie nad epidemiologia̧ cukrzycy (PWBEC 1998-2000). Pol Arch Med Wewn 2001; 106: 751.
6. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-4.
7. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987; 26: 481-512.
8. Bierin H, Knappe G, Gerl H, Lochs H. Prevelance of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 2000; 27: 27-31.
9. Bak JF, Mo/ller N, Schmitz O. Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am J Physiol 1991; 260: E736-42.
10. Hansen I, Tsalikian E, Beaufrere B, et al. Insuline resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986; 250: E269-73.
11. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle. Its role in insuline sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-9.
12. Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52: 549-55.
13. Muggeo M, Bar RS, Roth J, et al. The insulin resistance of acromegaly: evidence for two alterations in the insulin receptor on circulating monocytes. J Clin Endocrinol Metab 1979; 24: 23-52.
14. Sönksen P, Greenwood FC, Ellis JP, et al. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 1967; 27: 1418-30.
15. Ho KK, Jenkins AB, Furler SM, et al. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992; 36: 271-9.
16. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997; 82: 2777-81.
17. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130: 581-6.
18. Ronchi C, Epaminonda P, Cappiello V, et al. Effects of the two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002; 25: 502-7.
19. Colao A, Auriemma RS, Pivonello R, et al. Medical consequences of acromegaly: what are the effects of biochemical control? Rev Endocr Metab Disord 2008; 9: 21-31.
20. Baldelli R. Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003; 59: 492-9.
21. Colao A, Auriemma RS, Galdiero M, et al. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 2009; 94: 528-37.
22. Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G. Additional metabolic effects of adding GH receptor or antagonist to long-acting somatostatin analog in patient with active acromegaly. Neuro Endocrinol Lett 2008; 29: 571-6.
23. Watanabe A, Komine F, Nirei K, et al. A case of secondary diabetes mellitus with acromegaly improved by pioglitazone. Diabet Med 2004; 21: 1049-50.
24. Ali O, Banerjee S, Kelly DF, Lee PD. Management of the diabetes mellitus associated with pituitary gigantism. Pituitary 2007; 10: 359-64.
25. Jørgensen JO, Krag M, Jessen N, et al. Growth hormone and glucose homeostasis. Horm Res 2004; 62 (Suppl 3): 51-5.
26. Jørgensen JO, Nørrelund H, Conceicao F, et al. Somatropin and glucose homeostasis: consideration for patient management. Treat Endocrinol 2002; 1: 229-34.
27. Monson JP, Begtsson BA, Abs R, et al. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000; 355: 1728-9.
28. Hartman ML. Review of HypoCCS data proceeding of the Am Endo Soc Conference 2001.
29. Peracchi M, Porretti S, Gebbia C, et al. Incerase glucose--dependent insulinotropic polypeptide secretion in acromegaly. Eur J Endocrinol 2001; 145: R1-4.
30. CappielloV, Ronchi, Morpurgo PS, et al. Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. Eur J Endocrinol 2002; 147: 189-94.